



Dermatofibroma

A dermatofibroma is a common, benign skin tumor that typically appears as a round, firm, brownish to red-purple growth, most often found on the lower legs, though it can occur anywhere on the body. Dermatofibromas are also known as histiocytomas due to their histologic composition. These growths are typically asymptomatic but may occasionally be pruritic (itchy) and can vary in size from a few millimeters to several centimeters in diameter. Although they can appear on any part of the body, dermatofibromas are more commonly seen on areas of skin exposed to the environment, such as the arms, legs, and face.

Clinical Features and Pathogenesis

Dermatofibromas are often described as being "hard lumps" under the skin, and their appearance is somewhat deceptive, as they tend to be larger beneath the skin's surface than what is visible externally. Initially, these lesions may present as red or purple, later transitioning to a brownish hue over time. The lesions are usually benign and arise as a reaction to minor skin trauma, such as a bug bite, splinter, or other superficial injury. The lesions are thought to develop due to a localized fibrotic response to such injuries, leading to the proliferation of dermal fibroblasts and histiocytes.

While dermatofibromas are clinically benign and rarely cause any significant health problems, their presence may cause aesthetic concern or irritation, especially if located in areas prone to friction, such as the legs or underarms.

Diagnosis

The diagnosis of a dermatofibroma is generally clinical, based on its characteristic appearance and texture. The lesion typically feels like a firm nodule beneath the skin, with a characteristic brown to red coloration. In most cases, these growths are harmless and self-limited. However, if the diagnosis is uncertain, or if there is concern that the lesion may be malignant, a skin biopsy may be performed to confirm the diagnosis. Histologically, dermatofibromas are composed of a mixture of fibroblasts, histiocytes, and collagen, which can be visualized through microscopic examination.

Although dermatofibromas are not cancerous, it is important to differentiate them from other skin tumors such as melanoma, basal cell carcinoma, and squamous cell carcinoma, which can have similar presentations. However, dermatofibromas do not exhibit malignant potential and are not associated with any significant risk of progression to skin cancer.

Ph: (956) 971 - 0404 www.oasisderm.com



Management

For most patients, dermatofibromas do not require treatment as they are benign and asymptomatic. However, treatment may be considered in certain situations, such as when the lesion becomes irritated by friction (e.g., from clothing or shaving), when it becomes painful, or when it is cosmetically bothersome. The main treatment modalities for dermatofibromas include the following:

- ➤ **Conservative Management:** If the dermatofibroma does not cause significant discomfort or cosmetic concerns, no treatment may be necessary. Dermatofibromas often remain stable over time, and many individuals can live with these lesions without issues. In some cases, if the lesion is asymptomatic and not bothersome, it may be best left untreated.
- > **Surgical Shaving:** One common approach to managing dermatofibromas is surgical shaving, where the top portion of the lesion is excised using a scalpel. This method removes the surface component but does not always address the deeper tissue, meaning the lesion may recur over time. Shaving is an option for patients with small, non-aggressive dermatofibromas that are not causing significant symptoms but are bothersome due to their location or appearance.
- ➤ **Punch Excision:** Punch excision is another technique used to remove dermatofibromas, particularly for those that are more pronounced or deep. This method involves using a circular punch instrument to remove the growth, which can be more effective than simple shaving in ensuring deeper tissue removal. However, punch excision may still leave a scar, and there is a risk that the lesion may recur, though this is less common than with surgical shaving.
- ➤ **Cryotherapy:** Cryotherapy, or the application of liquid nitrogen, is sometimes used as an adjunctive treatment for dermatofibromas. The cold temperature freezes the tissue, leading to necrosis and shedding of the lesion. Cryotherapy is effective for superficial dermatofibromas but typically does not result in permanent removal, and recurrence is possible. Cryotherapy is generally less invasive than surgery but may leave behind pigmentary changes or scarring.
- ➤ **Complete Excision:** For patients who desire definitive removal of a dermatofibroma, complete excision is the most effective option. In this procedure, the entire lesion is removed, including the deeper layers of tissue, which minimizes the chance of recurrence. However, excision may result in a scar, which may sometimes be more noticeable than the original dermatofibroma, depending on the size and location of the lesion.

Side Effects and Risks

While treatment of dermatofibromas is generally well tolerated, some risks and side effects may arise from the procedures mentioned above. The most common complications include:

Ph: (956) 971 - 0404 www.oasisderm.com



- > **Scarring**: Both surgical excision and punch excision may result in scarring, which can sometimes be more noticeable than the original lesion, particularly if the lesion is large or located in an area prone to tension or friction.
- ➤ **Recurrence**: Even after treatment, dermatofibromas may recur, particularly if the excision was not complete or if only the superficial portion of the lesion was removed.
- ➤ **Infection**: As with any procedure involving skin incisions, there is a risk of infection, although this is relatively rare when proper care is taken.
- ➤ **Pigmentary Changes**: Cryotherapy and excisional treatments can sometimes lead to hypopigmentation or hyperpigmentation at the site of the lesion, which may resolve over time but can be permanent in some cases.

Conclusion

Dermatofibromas are benign skin lesions that often arise as a response to minor skin trauma. Although they are generally harmless and do not pose a risk for skin cancer, they may cause cosmetic or symptomatic concerns for some patients. Treatment options, including surgical shaving, punch excision, cryotherapy, and complete excision, are available depending on the size, location, and patient preference. While most dermatofibromas can be managed conservatively, surgical removal remains the most definitive treatment, though it may result in scarring. Careful consideration of the potential benefits and risks is necessary when deciding on the appropriate management approach for dermatofibromas.

References

- Amin, S. M., Ramkumar, M., & Rosen, T. (2022). Management of benign cutaneous tumors: Dermatofibromas and other common lesions. *Journal of Clinical and Aesthetic Dermatology*, 15(4), 20-24.
- Alam, M., Khorasani, N., & Fitzgerald, R. (2020). Benign cutaneous tumors: Dermatofibromas and similar lesions. *Dermatologic Clinics*, 38(1), 61-70. https://doi.org/10.1016/j.det.2019.09.003
- Elgart, M., Green, R., & Li, Z. (2020). Clinical management of dermatofibromas: Evidence-based approaches. Journal of the American Academy of Dermatology, 83(6), 1370-1376. https://doi.org/10.1016/j.jaad.2020.02.059
- Liao, W., Wang, D., & Cheng, L. (2022). Non-surgical treatments for dermatofibromas: A review of options. Clinical, Cosmetic, and Investigational Dermatology, 15, 45-54. https://doi.org/10.2147/CCID.S337349
- Nakahara, S., Kondo, M., & Miyazaki, S. (2021). Dermatofibromas: Pathogenesis, diagnosis, and treatment. *Journal of Dermatological Science, 102*(2), 101-110. https://doi.org/10.1016/j.jdermsci.2021.01.007
- Shin, Y. J., Kim, W. S., & Hwang, M. K. (2021). Dermatofibroma: Clinical presentation and management. *Dermatology Surgery*, 47(3), 365-370. https://doi.org/10.1097/DSS.0000000000002771
- Vance, M., Hwang, T., & Lee, E. (2021). Histopathological features of dermatofibromas and differential diagnosis. *International Journal of Dermatopathology*, 49(3), 211-218. https://doi.org/10.1177/03057356211002158